Wound Care Biologics Market
Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties.
Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity. Demand for wound care biologic products is expected to increase significantly as early intervention of diabetic ulcer can prevent severe complications such as infection, hospitalization, and amputation. Wound care biologics market is expected to gain significant traction, as the commercially available skin substitutes have clinical and experimental evidence of efficacy in wound healing.
“The global wound care biologics market was valued at US$ 1.2 billion in 2016 and is expected to exhibit a robust CAGR of 6.9% over the forecast period (2017–2025).”
Request Sample Copy Of This Business Report:
Increasing incidences of chronic ulcers, owing to rising prevalence of diabetes, increasing surgical procedures, and rise in trauma cases are major driving factors for growth of wound care biologics market. According to the survey by World Health Organization, 2014, injuries resulting from traffic collisions, drowning, poisoning, falls or burns account for 9% of the global mortality. Also, according to a study by BMJ Journal Injury Prevention, 2013, an estimated 973 million people sustained injuries that warranted some type of healthcare and 4.8 million people died from injuries. The Journal also stated that major injury causes included road injury (29.1%), self-harm (17.6%), falls (11.6%), and interpersonal violence (8.5%). Manufacturers are also focused on extensive research and development to develop new products and expand their product portfolio. For instance, in 2016, Integra LifeSciences Holdings Corporation received FDA approval for Integra Dermal Regeneration Template (IDRT) for the treatment of diabetic foot ulcers that is marketed under the name of Integra Omnigraft Dermal Regeneration Matrix. Moreover, public awareness for biologics has positively contributed to the market growth, as people are opting for enhanced medical care for preventing wounds to minimize the morbidity associated with the formation of chronic wounds. However, higher cost of the biologics and stringent regulatory approvals for launch of innovative tissue engineered products are hindering growth of the wound care biologics market.
Global Wound Care Biologics Market, By Product Type:
Biologic Skin Substitutes
Enzyme Based Formulations
Asia Pacific is expected to exhibit significant growth in the global wound care biologics market over the forecast period. This is owing to high prevalence of diabetic patients in Asian countries. According to the Indian Diabetes Research Foundation, 2016, around 60% of the world’s population suffering from diabetes lives in Asia, with around one-half in China and India combined. The Foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes, the number for which is expected to rise to 201.8 million by 2035.
Increasing incidence of chronic wounds and ulcers to accelerate the market growth
Chronic wounds have a significant impact on the health and quality of life of patients and their families, causing pain, emotional stress, restriction on daily activities, depression, distress, and anxiety, with prolonged hospital stay and chronic morbidity. According to the Advances in Wound Care Journal, 2015, chronic leg and foot ulcers last for around 12 months on an average, with recurrence affecting up to 65% of patients, leading to loss of function and decreased quality of life.
Major players operating in the global wound care biologics market are Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.